Literature DB >> 33951186

The EFIS vaccination task force expert report.

Alexandros Sarantopoulos1,2, Doug Brown2, Ursula Wiedermann2, Carmen Alvarez Dominguez2, Christian Bogdan2, İhsan Gürsel2, Srđa Janković2, Claude LeClerc2, Massimo Locati2, Anne Spurkland2, Frederico Regateiro2, Pierre Van Damme2, Aurelija Žvirblienė2, Felix M Wensveen2,3.   

Abstract

Year:  2021        PMID： 33951186      PMCID： PMC8206916          DOI： 10.1002/eji.202170056

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


× No keyword cloud information.
  10 in total

1.  The COVID-19 vaccine development landscape.

Authors:  Tung Thanh Le; Zacharias Andreadakis; Arun Kumar; Raúl Gómez Román; Stig Tollefsen; Melanie Saville; Stephen Mayhew
Journal:  Nat Rev Drug Discov       Date:  2020-05       Impact factor: 84.694

2.  Risk of SARS-CoV-2 reinfection after natural infection.

Authors:  Rosemary J Boyton; Daniel M Altmann
Journal:  Lancet       Date:  2021-03-17       Impact factor: 79.321

3.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

Authors:  Zijun Wang; Fabian Schmidt; Yiska Weisblum; Frauke Muecksch; Christopher O Barnes; Shlomo Finkin; Dennis Schaefer-Babajew; Melissa Cipolla; Christian Gaebler; Jenna A Lieberman; Thiago Y Oliveira; Zhi Yang; Morgan E Abernathy; Kathryn E Huey-Tubman; Arlene Hurley; Martina Turroja; Kamille A West; Kristie Gordon; Katrina G Millard; Victor Ramos; Justin Da Silva; Jianliang Xu; Robert A Colbert; Roshni Patel; Juan Dizon; Cecille Unson-O'Brien; Irina Shimeliovich; Anna Gazumyan; Marina Caskey; Pamela J Bjorkman; Rafael Casellas; Theodora Hatziioannou; Paul D Bieniasz; Michel C Nussenzweig
Journal:  Nature       Date:  2021-02-10       Impact factor: 69.504

4.  SARS-CoV-2 neutralizing antibody development strategies.

Authors:  Bertan Koray BalcioĞlu; Melis Denİzcİ ÖncÜ; Hasan Ümit ÖztÜrk; Fatıma YÜcel; Filiz Kaya; Müge Serhatli; Hivda ÜlbeĞİ Polat; Şaban Tekİn; Aylin Özdemİr Bahadir
Journal:  Turk J Biol       Date:  2020-06-21

5.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Authors:  Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Science       Date:  2021-01-06       Impact factor: 47.728

6.  Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.

Authors:  Rita Carsetti; Salvatore Zaffina; Eva Piano Mortari; Sara Terreri; Francesco Corrente; Claudia Capponi; Patrizia Palomba; Mattia Mirabella; Simona Cascioli; Paolo Palange; Ilaria Cuccaro; Cinzia Milito; Alimuddin Zumla; Markus Maeurer; Vincenzo Camisa; Maria Rosaria Vinci; Annapaola Santoro; Eleonora Cimini; Luisa Marchioni; Emanuele Nicastri; Fabrizio Palmieri; Chiara Agrati; Giuseppe Ippolito; Ottavia Porzio; Carlo Concato; Andrea Onetti Muda; Massimiliano Raponi; Concetta Quintarelli; Isabella Quinti; Franco Locatelli
Journal:  Front Immunol       Date:  2020-12-16       Impact factor: 7.561

7.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.

Authors:  Sam Abbott; Rosanna C Barnard; Christopher I Jarvis; Adam J Kucharski; James D Munday; Carl A B Pearson; Timothy W Russell; Damien C Tully; Alex D Washburne; Tom Wenseleers; Nicholas G Davies; Amy Gimma; William Waites; Kerry L M Wong; Kevin van Zandvoort; Justin D Silverman; Karla Diaz-Ordaz; Ruth Keogh; Rosalind M Eggo; Sebastian Funk; Mark Jit; Katherine E Atkins; W John Edmunds
Journal:  Science       Date:  2021-03-03       Impact factor: 63.714

8.  Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection.

Authors:  Yan-Ying Fan; Zi-Tong Huang; Li Li; Man-Hui Wu; Tao Yu; Richard A Koup; Robert T Bailer; Chang-You Wu
Journal:  Arch Virol       Date:  2009-06-13       Impact factor: 2.574

9.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Authors:  Ugur Sahin; Alexander Muik; Evelyna Derhovanessian; Isabel Vogler; Lena M Kranz; Mathias Vormehr; Alina Baum; Kristen Pascal; Jasmin Quandt; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Carsten Boesler; Corinna Rosenbaum; Marie-Cristine Kühnle; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Katalin Karikó; Tania Palanche; Boris Fischer; Armin Schultz; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Kena A Swanson; Jakob Loschko; Ingrid L Scully; Mark Cutler; Warren Kalina; Christos A Kyratsous; David Cooper; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2020-09-30       Impact factor: 49.962

Review 10.  COVID-19 vaccines: where we stand and challenges ahead.

Authors:  Guido Forni; Alberto Mantovani
Journal:  Cell Death Differ       Date:  2021-01-21       Impact factor: 15.828
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.